Literature DB >> 6740741

Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by reversed-phase liquid chromatography.

J S Schanche, P E Lønning, P M Ueland, S Kvinnsland.   

Abstract

A liquid chromatography method for the determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma is described. The assay involved precipitation of the plasma proteins using a mixture of acetonitrile and perchloric acid, without an extraction procedure. The supernatant was subjected to chromatography on a 3-micrometers ODS Hypersil column eluted isocratically with 11% acetonitrile in 100 mM ammonium formate buffer, pH 3.5. The absorbance was routinely recorded at 242 nm. The standard curves were linear in the range of 0.1-100 micrograms/ml, and the lower detection limit was approximately 0.1 microgram/ml for aminoglutethimide and its plasma metabolite N-acetylaminoglutethimide. The precision of the method, given as the coefficient of variation, was 3.9%. With this method, it was determined that aminoglutethimide and N-acetylaminoglutethimide were present in the plasma of patients receiving single-dose or continuous treatment with aminoglutethimide for breast cancer. No N-formylaminoglutethimide or nitroglutethimide could be demonstrated in the plasma from these patients. Interference from several drugs commonly given to patients with breast cancer was ruled out.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6740741     DOI: 10.1097/00007691-198406000-00016

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 4.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

5.  Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Authors:  P E Lønning; S Kvinnsland; T Thorsen; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

6.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer.

Authors:  P E Lønning; P M Ueland; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.

Authors:  P E Lønning; D C Johannessen; T Thorsen
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.